Reuters logo
5 months ago
BRIEF-In first phase 3 trial Merck's virus vaccine (V2120 reduced the incidence of confirmed herpes zoster cases
February 24, 2017 / 9:07 PM / 5 months ago

BRIEF-In first phase 3 trial Merck's virus vaccine (V2120 reduced the incidence of confirmed herpes zoster cases

1 Min Read

Feb 24 (Reuters) - Merck & Co Inc:

* In first phase 3 trial, Merck's investigational inactivated varicella zoster virus vaccine (V212) reduced the incidence of confirmed herpes zoster cases by an estimated 64 percent in immunocompromised subjects

* Merck & Co Inc - in trial, V212 met its primary endpoint

* Merck & Co Inc - secondary endpoint findings from study showed that V212 reduced incidence of moderate-to-severe hz pain by an estimated 69.5 percent

* Merck & Co Inc - in addition, v212 showed reduction of other hz complications by an estimated 73.5 percent

* Merck & Co - in trial, V212 demonstrated an estimated 83.7 percent reduction of incidence of post-herpetic neuralgia beyond 90 days after onset of hz

* Merck- look forward to exploring data further, reviewing results of additional phase 3 study that is underway in immunocompromised patients with malignancies Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below